The SI of MFI of ROS-producing PMN ( Supplementary Table 3 ) remained at the same level for 4 h after the immune challenge and showed the significant highest capacity at 9 h pi , followed by a reduction to baseline values until the end of the trial
Numerous studies (135-178) have indicated that GLP-1RAs can reduce oxidative stress, inflammatory responses, apoptosis and mitochondrial dysfunction, improve insulin resistance, and induce myogenic differentiation, thereby showing potential in the treatment of SIM
Kennedy et al
Lack of early weight loss may indicate inadequate dosing, poor medication adherence, or underlying metabolic factors
How do GLP-1 drugs support metabolic weight loss
The medication must be coupled with a healthy diet, lifestyle intervention for a sustainable weight loss in the long run